LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub

• Made possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club – Everton in the Community – the Liverpool-based hub will provide significant support for individuals suffering from chronic breathlessness and other heart and lung-related conditions in a community-based setting.
• The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick sample.
• Run on the LumiraDx Platform, the LumiraDx NT-proBNP test is a smart, automated, highly portable diagnostic solution designed to improve access and ease of use for heart health checks, all within 12 minutes.
• Covering multiple clinical areas, the LumiraDx Platform is also ideally placed for lung-related health checks and other cardiometabolic disease screening, offering HbA1c, CRP, D-Dimer, Influenza A/B, RSV & SARS-CoV-2 Antigen Tests; all on a single Platform.*
  

LONDON, Oct. 20, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, is pleased to announce a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub, set to go live in November.

The official charity of Everton Football Club will run this novel screening hub from the recently opened People’s Place. The hub will provide the Merseyside community with access to the latest technologies and specialist input from a multidisciplinary team of primary care, heart, and lung specialists to focus on early diagnosis and early treatment for chronic breathlessness in a walk-in setting.

Michael Salla, Deputy CEO for Everton in the Community, said, “We’re delighted to be launching this project, which is the first screening service of its kind for heart failure, COPD and asthma in England. It will use next generation diagnostics that don’t require phlebotomy, while also using artificial intelligence to help detect heart failure and prevent premature mortality alongside reducing the complications of these conditions due to the early detection. We can’t thank AstraZeneca enough for their support to make this happen.”

The heart and lung screening hub will work to raise awareness of medical conditions which cause chronic breathlessness, offer screenings for heart failure, chronic obstructive pulmonary disease (COPD) and other chronic conditions which are common in the local population as well as offer lifestyle reviews and advice.